Shanghai Haohai Biological Technology’s $40 Million Investment in Eirion Therapeutics

Locke Lord LLP advised Shanghai Haohai Biological Technology Co. on the deal.

Shanghai Haohai Biological Technology Co., Ltd., a public company traded on the Hong Kong and Shanghai stock exchanges, announced its $40 million Series A preferred equity investment in Eirion Therapeutics, Inc., a biotech startup based in Massachusetts, and related licensing arrangements. 

Shanghai Haohai Biological Technology Co., Ltd. manufactures absorbable biomedical materials. The Company manufactures and sells intraocular lens, medical sodium hyaluronate, medical chitosan, medical collage sponge, and other products.

The Locke Lord team was led by Charles Wu, Douglas Gray (Picture) and Baker Coon. Additional assistance was provided by Ziwen Zhu and Lou Lou Yan (both of Atlanta), Ralph Loren and Brandon Curtin (both of Boston), Katie Morin (Providence), Steve Murphy (Washington, D.C.) and Mark Backofen and Charles Phipps (both of Dallas).

Involved fees earner: Mark Backofen – Locke Lord; Baker Coon – Locke Lord; Brandon Curtin – Locke Lord; Douglas Gray – Locke Lord; Ralph Loren – Locke Lord; Kathrine Morin – Locke Lord; Stephen Murphy – Locke Lord; Charles Phipps – Locke Lord; Charles Wu – Locke Lord; Lou Lou Yan – Locke Lord; Ziwen Zhu – Locke Lord;

Law Firms: Locke Lord;

Clients: Shanghai Haohai Biological Technology Co.;

Author: Martina Bellini